Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus 10-day decitabine versus 10-day decitabine in unfit adult AML or high-risk MDS
NL-OMON55438Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing 10-day decitabine with 10-day decitabine + midostaurin (2 arms). Primary endpoint: Cumulative CR/CRi rate during 3 cycles. Started Jan 2020; status: recruiting.
02
Drugs
midostaurindecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55438.